학술논문
121 - A PHASE I TRIAL OF TARGETED IMMUNOTHERAPY WITH DARATUMUMAB FOLLOWING MYELOABLATIVE TOTAL BODY IRRADIATION (TBI)-BASED CONDITIONING AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATON IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH HIGH-RISK T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOMA (T- ALL/T-LLy) (ALLO-T-DART) (IND 159396): A PTCTC FACILITATED STUDY
Document Type
Abstract
Author
Quigg, T.; Flower, A.; Teachey, D.; Lim, M.; Chu, Y.; Harrison, L.; Morris, E.; Gardenswartz, A.; Hochberg, J.; Ozkaynak, M.; Rosenblum, J.; Milner, J.; Pehlivan, K.; Levendoglu-Tugal, O.; Fabricatore, S.; Wolownik, K.; Ayello, J.; Rigot, O.; Klejmont, L.; Campbell, M.; Gonzalez, I.; Otero, N.; Budhram, A.; Mintzer, E.; Mahanti, H.; Dufresne, J.; Liu, D.; Ahmed, T.; Steinberg, A.; Sweeney, R.; McHale, P.; Islam, H.; Gerard, P.; Moorthy, C.; Voss, S.; Miles, R.; Audino, A.; Mo, X.; Stanek, J.; Olshen, A.; Hermiston, M.; Seif, A.; Cairo, M.
Source
In Leukemia Research October 2022 121 Supplement:S71-S73
Subject
Language
ISSN
0145-2126